Patents by Inventor Jonathan Alexander Terrett

Jonathan Alexander Terrett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
    Patent number: 10577420
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 3, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • METHODS AND COMPOSITIONS FOR TREATING CANCER
    Publication number: 20200063100
    Abstract: Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
    Type: Application
    Filed: May 10, 2019
    Publication date: February 27, 2020
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Mary-Lee DEQUÉANT, Zinkal Samir PADALIA
  • ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190382493
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 19, 2019
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T.L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20190365808
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: June 4, 2019
    Publication date: December 5, 2019
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20190365809
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: June 6, 2019
    Publication date: December 5, 2019
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • ANTIBODIES TO BONE MARROW STROMAL ANTIGEN 1
    Publication number: 20190322764
    Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.
    Type: Application
    Filed: February 26, 2019
    Publication date: October 24, 2019
    Applicant: Oxford BioTherapeutics Ltd
    Inventors: Christian ROHLFF, Jonathan Alexander TERRETT
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20190314413
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20190314414
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
  • ANTI-ITGA3 ANTIBODIES, ACTIVATABLE ANTI-ITGA3 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190309072
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: January 18, 2019
    Publication date: October 10, 2019
    Inventors: Jason Gary SAGERT, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
    Publication number: 20190241652
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: January 20, 2016
    Publication date: August 8, 2019
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190202927
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 13, 2018
    Publication date: July 4, 2019
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
    Patent number: 10336824
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: July 2, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T. L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20190111150
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventors: Shweta SINGH, Jennifer Hope RICHARDSON, Laura Patterson SERWER, Jonathan Alexander TERRETT, Susan E. MORGAN-LAPPE, Tracy HENRIQUES, Sherry L. RALSTON, Marvin Robert LEANNA, Ilaria BADAGNANI, Sahana BOSE
  • CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
    Publication number: 20190106506
    Abstract: The invention provides antibodies which bind to LY75. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer, esophageal cancer, skin cancer, thyroid cancer, lung cancer, bladder cancer, multiple myeloma and lymphoma.
    Type: Application
    Filed: September 24, 2018
    Publication date: April 11, 2019
    Applicant: OXFORD BIOTHERAPEUTICS LTD
    Inventors: Jonathan Alexander Terrett, James Edward Ackroyd
  • Nucleic acid encoding bone marrow stromal antigen 1 antibody
    Patent number: 10239956
    Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: March 26, 2019
    Assignee: Oxford BioTherapeutics Ltd
    Inventors: Christian Rohlff, Jonathan Alexander Terrett
  • Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
    Patent number: 10233244
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 19, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
    Patent number: 10179817
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 15, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20180325955
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 15, 2018
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • CD147 ANTIBODIES, ACTIVATABLE CD147 ANTIBODIES, AND METHODS OF MAKING AND USE THEREOF
    Publication number: 20180303952
    Abstract: The invention relates generally to antibodies that bind CD147, activatable antibodies that bind to CD147 and methods of making and using these antibodies and activatable antibodies in a variety of therapeutic, prophylactic, and diagnostic contexts. In some embodiments, the CD147 antibodies and CD147 activatable antibodies bind human and cynomolgus monkey CD147.
    Type: Application
    Filed: March 9, 2018
    Publication date: October 25, 2018
    Inventors: Jason Gary SAGERT, Shuoyen Jack Lin, James William West, Jonathan Alexander Terrett
  • Conjugated antibodies against LY75 for the treatment of cancer
    Patent number: 10081682
    Abstract: The invention provides antibodies which bind to LY75. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer, esophageal cancer, skin cancer, thyroid cancer, lung cancer, bladder cancer, multiple myeloma and lymphoma.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: September 25, 2018
    Assignee: Oxford Bio Therapeutics Ltd.
    Inventors: Jonathan Alexander Terrett, James Edward Ackroyd